Puma Biotechnology | PBYI - Frais De Vente Et D'Administration

Prix De L'Action
7.78
Variation Quotidienne
-0.02 -0.26%
Mensuellement
29.67%
Annuel
175.89%
Q2 Prévisions
7.57




Frais De Vente Et D'Administration Changement Date
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amgen USD 1.94B 237M 2025-12
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Daiichi Sankyo JPY 228.23B 39.15B 2025-12
Esperion Therapeutics USD 39.42M 456K 2025-12
Exelixis USD 123.02M 19.9M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
Glaxosmithkline GBP 3.56B 650.29M 2025-12
Incyte USD 390.41M 61.33M 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
Moderna USD 308M 40M 2025-12
Novartis USD 3.44B 128M 2025-12
Pfizer USD 4.08B 894M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Takeda JPY 282.78B 29.23B 2025-12
TG Therapeutics USD 50.73M 12.64M 2025-12
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12